Compounds > ganoderic acid c2

Page last updated: 2024-11-13

ganoderic acid c2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	57396771
CHEMBL ID	1922174
CHEBI ID	168298
MeSH ID	M0556627

Synonyms (16)

Synonym
ganoderic acid c2
(2r,6r)-2-methyl-4-oxo-6-[(3s,5r,7s,10s,13r,14r,15s,17r)-3,7,15-trihydroxy-4,4,10,13,14-pentamethyl-11-oxo-1,2,3,5,6,7,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptanoic acid
CHEBI:168298
CHEMBL1922174 ,
bdbm50359040
103773-62-2
AC-34472
3,7,15-trihydroxy-11,23-dioxo-, (3b,7b,15a,25r)-
lanost-8-en-26-oicacid
ganoderic acid c 2
lanost-8-en-26-oicacid, 3,7,15-trihydroxy-11,23-dioxo-, (3b,7b,15a,25r)-
HY-N1517
CS-0017060
MS-29623
ganodericacidc2
AKOS040760408

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
triterpenoid	Any terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Aldo-keto reductase family 1 member B1	Homo sapiens (human)	IC50 (µMol)	43.8000	0.0010	1.1913	10.0000	AID631922
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Tumor necrosis factor	Homo sapiens (human)	Kd	0.0084	0.0027	4.2926	9.7700	AID1156798
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (192)

Process	via Protein(s)	Taxonomy
positive regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
negative regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
positive regulation of MAP kinase activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of MAPK cascade	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-33 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory response	Tumor necrosis factor	Homo sapiens (human)
negative regulation of miRNA transcription	Tumor necrosis factor	Homo sapiens (human)
positive regulation of miRNA transcription	Tumor necrosis factor	Homo sapiens (human)
negative regulation of signaling receptor activity	Tumor necrosis factor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Tumor necrosis factor	Homo sapiens (human)
positive regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
negative regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-8 production	Tumor necrosis factor	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tumor necrosis factor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascade	Tumor necrosis factor	Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory response	Tumor necrosis factor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Tumor necrosis factor	Homo sapiens (human)
positive regulation of synoviocyte proliferation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of I-kappaB phosphorylation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Tumor necrosis factor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Tumor necrosis factor	Homo sapiens (human)
response to hypoxia	Tumor necrosis factor	Homo sapiens (human)
microglial cell activation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of cytokine production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein phosphorylation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of endothelial cell proliferation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of L-glutamate import across plasma membrane	Tumor necrosis factor	Homo sapiens (human)
macrophage activation involved in immune response	Tumor necrosis factor	Homo sapiens (human)
chronic inflammatory response to antigenic stimulus	Tumor necrosis factor	Homo sapiens (human)
leukocyte migration involved in inflammatory response	Tumor necrosis factor	Homo sapiens (human)
regulation of immunoglobulin production	Tumor necrosis factor	Homo sapiens (human)
negative regulation of cytokine production involved in immune response	Tumor necrosis factor	Homo sapiens (human)
positive regulation of chronic inflammatory response to antigenic stimulus	Tumor necrosis factor	Homo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulin	Tumor necrosis factor	Homo sapiens (human)
skeletal muscle contraction	Tumor necrosis factor	Homo sapiens (human)
negative regulation of systemic arterial blood pressure	Tumor necrosis factor	Homo sapiens (human)
glucose metabolic process	Tumor necrosis factor	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Tumor necrosis factor	Homo sapiens (human)
inflammatory response	Tumor necrosis factor	Homo sapiens (human)
humoral immune response	Tumor necrosis factor	Homo sapiens (human)
JNK cascade	Tumor necrosis factor	Homo sapiens (human)
circadian rhythm	Tumor necrosis factor	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Tumor necrosis factor	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Tumor necrosis factor	Homo sapiens (human)
response to xenobiotic stimulus	Tumor necrosis factor	Homo sapiens (human)
response to virus	Tumor necrosis factor	Homo sapiens (human)
response to salt stress	Tumor necrosis factor	Homo sapiens (human)
response to fructose	Tumor necrosis factor	Homo sapiens (human)
negative regulation of heart rate	Tumor necrosis factor	Homo sapiens (human)
vascular endothelial growth factor production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
negative regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
negative regulation of lipid storage	Tumor necrosis factor	Homo sapiens (human)
response to activity	Tumor necrosis factor	Homo sapiens (human)
regulation of metabolic process	Tumor necrosis factor	Homo sapiens (human)
calcium-mediated signaling	Tumor necrosis factor	Homo sapiens (human)
extracellular matrix organization	Tumor necrosis factor	Homo sapiens (human)
osteoclast differentiation	Tumor necrosis factor	Homo sapiens (human)
sequestering of triglyceride	Tumor necrosis factor	Homo sapiens (human)
cortical actin cytoskeleton organization	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein-containing complex assembly	Tumor necrosis factor	Homo sapiens (human)
positive regulation of fever generation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of myelination	Tumor necrosis factor	Homo sapiens (human)
response to nutrient levels	Tumor necrosis factor	Homo sapiens (human)
negative regulation of interleukin-6 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of chemokine production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of fractalkine production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of type II interferon production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-18 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-6 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-8 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Tumor necrosis factor	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Tumor necrosis factor	Homo sapiens (human)
positive regulation of heterotypic cell-cell adhesion	Tumor necrosis factor	Homo sapiens (human)
toll-like receptor 3 signaling pathway	Tumor necrosis factor	Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activity	Tumor necrosis factor	Homo sapiens (human)
response to isolation stress	Tumor necrosis factor	Homo sapiens (human)
response to macrophage colony-stimulating factor	Tumor necrosis factor	Homo sapiens (human)
vasodilation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Tumor necrosis factor	Homo sapiens (human)
positive regulation of apoptotic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of programmed cell death	Tumor necrosis factor	Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction	Tumor necrosis factor	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Tumor necrosis factor	Homo sapiens (human)
negative regulation of protein-containing complex disassembly	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein-containing complex disassembly	Tumor necrosis factor	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of MAP kinase activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of MAPK cascade	Tumor necrosis factor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tumor necrosis factor	Homo sapiens (human)
positive regulation of JUN kinase activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of neuron apoptotic process	Tumor necrosis factor	Homo sapiens (human)
negative regulation of blood vessel endothelial cell migration	Tumor necrosis factor	Homo sapiens (human)
negative regulation of viral genome replication	Tumor necrosis factor	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Tumor necrosis factor	Homo sapiens (human)
response to ethanol	Tumor necrosis factor	Homo sapiens (human)
regulation of fat cell differentiation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of fat cell differentiation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of myoblast differentiation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of osteoblast differentiation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of osteoclast differentiation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein catabolic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of action potential	Tumor necrosis factor	Homo sapiens (human)
positive regulation of cell adhesion	Tumor necrosis factor	Homo sapiens (human)
positive regulation of mitotic nuclear division	Tumor necrosis factor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Tumor necrosis factor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Tumor necrosis factor	Homo sapiens (human)
negative regulation of mitotic cell cycle	Tumor necrosis factor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tumor necrosis factor	Homo sapiens (human)
positive regulation of translational initiation by iron	Tumor necrosis factor	Homo sapiens (human)
negative regulation of glucose import	Tumor necrosis factor	Homo sapiens (human)
positive regulation of JNK cascade	Tumor necrosis factor	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Tumor necrosis factor	Homo sapiens (human)
astrocyte activation	Tumor necrosis factor	Homo sapiens (human)
embryonic digestive tract development	Tumor necrosis factor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of inflammatory response	Tumor necrosis factor	Homo sapiens (human)
negative regulation of neurogenesis	Tumor necrosis factor	Homo sapiens (human)
regulation of insulin secretion	Tumor necrosis factor	Homo sapiens (human)
positive regulation of synaptic transmission	Tumor necrosis factor	Homo sapiens (human)
regulation of synapse organization	Tumor necrosis factor	Homo sapiens (human)
defense response to Gram-positive bacterium	Tumor necrosis factor	Homo sapiens (human)
cognition	Tumor necrosis factor	Homo sapiens (human)
leukocyte tethering or rolling	Tumor necrosis factor	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	Tumor necrosis factor	Homo sapiens (human)
negative regulation of lipid catabolic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysis	Tumor necrosis factor	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein transport	Tumor necrosis factor	Homo sapiens (human)
response to glucocorticoid	Tumor necrosis factor	Homo sapiens (human)
positive regulation of hair follicle development	Tumor necrosis factor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tumor necrosis factor	Homo sapiens (human)
regulation of synaptic transmission, glutamatergic	Tumor necrosis factor	Homo sapiens (human)
positive regulation of glial cell proliferation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of vitamin D biosynthetic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of calcidiol 1-monooxygenase activity	Tumor necrosis factor	Homo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesis	Tumor necrosis factor	Homo sapiens (human)
regulation of branching involved in salivary gland morphogenesis	Tumor necrosis factor	Homo sapiens (human)
negative regulation of vascular wound healing	Tumor necrosis factor	Homo sapiens (human)
negative regulation of branching involved in lung morphogenesis	Tumor necrosis factor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Tumor necrosis factor	Homo sapiens (human)
cellular response to lipopolysaccharide	Tumor necrosis factor	Homo sapiens (human)
cellular response to amino acid stimulus	Tumor necrosis factor	Homo sapiens (human)
cellular response to retinoic acid	Tumor necrosis factor	Homo sapiens (human)
cellular response to nicotine	Tumor necrosis factor	Homo sapiens (human)
cellular response to type II interferon	Tumor necrosis factor	Homo sapiens (human)
cellular response to ionizing radiation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of mononuclear cell migration	Tumor necrosis factor	Homo sapiens (human)
positive regulation of podosome assembly	Tumor necrosis factor	Homo sapiens (human)
endothelial cell apoptotic process	Tumor necrosis factor	Homo sapiens (human)
protein localization to plasma membrane	Tumor necrosis factor	Homo sapiens (human)
negative regulation of oxidative phosphorylation	Tumor necrosis factor	Homo sapiens (human)
inflammatory response to wounding	Tumor necrosis factor	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Tumor necrosis factor	Homo sapiens (human)
cellular response to toxic substance	Tumor necrosis factor	Homo sapiens (human)
liver regeneration	Tumor necrosis factor	Homo sapiens (human)
necroptotic signaling pathway	Tumor necrosis factor	Homo sapiens (human)
negative regulation of bile acid secretion	Tumor necrosis factor	Homo sapiens (human)
antiviral innate immune response	Tumor necrosis factor	Homo sapiens (human)
response to Gram-negative bacterium	Tumor necrosis factor	Homo sapiens (human)
positive regulation of neuroinflammatory response	Tumor necrosis factor	Homo sapiens (human)
negative regulation of amyloid-beta clearance	Tumor necrosis factor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Tumor necrosis factor	Homo sapiens (human)
positive regulation of amyloid-beta formation	Tumor necrosis factor	Homo sapiens (human)
response to L-glutamate	Tumor necrosis factor	Homo sapiens (human)
positive regulation of neutrophil activation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Tumor necrosis factor	Homo sapiens (human)
regulation of establishment of endothelial barrier	Tumor necrosis factor	Homo sapiens (human)
negative regulation of bicellular tight junction assembly	Tumor necrosis factor	Homo sapiens (human)
cellular response to amyloid-beta	Tumor necrosis factor	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cell	Tumor necrosis factor	Homo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cell	Tumor necrosis factor	Homo sapiens (human)
regulation of membrane lipid metabolic process	Tumor necrosis factor	Homo sapiens (human)
response to 3,3',5-triiodo-L-thyronine	Tumor necrosis factor	Homo sapiens (human)
response to gold nanoparticle	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein localization to cell surface	Tumor necrosis factor	Homo sapiens (human)
positive regulation of blood microparticle formation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of hepatocyte proliferation	Tumor necrosis factor	Homo sapiens (human)
regulation of endothelial cell apoptotic process	Tumor necrosis factor	Homo sapiens (human)
regulation of reactive oxygen species metabolic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of DNA biosynthetic process	Tumor necrosis factor	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Tumor necrosis factor	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway	Tumor necrosis factor	Homo sapiens (human)
retinoid metabolic process	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
epithelial cell maturation	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
renal water homeostasis	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
carbohydrate metabolic process	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
prostaglandin metabolic process	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
C21-steroid hormone biosynthetic process	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
L-ascorbic acid biosynthetic process	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
regulation of urine volume	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
retinol metabolic process	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
negative regulation of apoptotic process	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
daunorubicin metabolic process	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
doxorubicin metabolic process	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
fructose biosynthetic process	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
cellular hyperosmotic salinity response	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
metanephric collecting duct development	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Tumor necrosis factor	Homo sapiens (human)
protease binding	Tumor necrosis factor	Homo sapiens (human)
cytokine activity	Tumor necrosis factor	Homo sapiens (human)
tumor necrosis factor receptor binding	Tumor necrosis factor	Homo sapiens (human)
protein binding	Tumor necrosis factor	Homo sapiens (human)
death receptor agonist activity	Tumor necrosis factor	Homo sapiens (human)
identical protein binding	Tumor necrosis factor	Homo sapiens (human)
retinal dehydrogenase activity	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
aldose reductase (NADPH) activity	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
protein binding	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
electron transfer activity	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activity	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
glyceraldehyde oxidoreductase activity	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
allyl-alcohol dehydrogenase activity	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
L-glucuronate reductase activity	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
glycerol dehydrogenase [NADP+] activity	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Process	via Protein(s)	Taxonomy
extracellular space	Tumor necrosis factor	Homo sapiens (human)
phagocytic cup	Tumor necrosis factor	Homo sapiens (human)
extracellular region	Tumor necrosis factor	Homo sapiens (human)
extracellular space	Tumor necrosis factor	Homo sapiens (human)
plasma membrane	Tumor necrosis factor	Homo sapiens (human)
external side of plasma membrane	Tumor necrosis factor	Homo sapiens (human)
cell surface	Tumor necrosis factor	Homo sapiens (human)
neuronal cell body	Tumor necrosis factor	Homo sapiens (human)
membrane raft	Tumor necrosis factor	Homo sapiens (human)
recycling endosome	Tumor necrosis factor	Homo sapiens (human)
cell surface	Tumor necrosis factor	Homo sapiens (human)
extracellular space	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
nucleoplasm	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
extracellular exosome	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay ID	Title	Year	Journal	Article
AID1156798	Binding affinity to TNF-alpha (unknown origin)	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID1156800	Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID1551892	Tmax in Sprague-Dawley rat at 300 mg/kg, po by LC-ESI-IT-TOF/MS analysis	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y.
AID779722	Inhibition of alpha-glucosidase (unknown origin) using sucrose as substrate assessed as formation of glucose after 30 mins by glucose oxidase method	2013	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21	Structure-activity relationships of lanostane-type triterpenoids from Ganoderma lingzhi as α-glucosidase inhibitors.
AID1156795	Retention time of the compound by chromatography	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID631922	Inhibition of recombinant human aldose reductase using dl-glyceraldehyde as substrate after 10 mins by spectrophotometry	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Structure-activity relationships of ganoderma acids from Ganoderma lucidum as aldose reductase inhibitors.
AID711438	Cytotoxicity against mouse P388 cells	2012	Journal of natural products, Nov-26, Volume: 75, Issue:11	Lanostanoids from fungi: a group of potential anticancer compounds.
AID711439	Cytotoxicity against human Bel7402 cells	2012	Journal of natural products, Nov-26, Volume: 75, Issue:11	Lanostanoids from fungi: a group of potential anticancer compounds.
AID711437	Cytotoxicity against human SGC7901 cells	2012	Journal of natural products, Nov-26, Volume: 75, Issue:11	Lanostanoids from fungi: a group of potential anticancer compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	8 (80.00)	24.3611
2020's	2 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	13.07 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	5.47 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (13.07)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (20.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
etoposide [no description available]	3.17	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.6	1	D-glucopyranose	epitope; mouse metabolite
eburicoic acid eburicoic acid: structure	3.17	1
10-hydroxycamptothecin [no description available]	3.17	1	pyranoindolizinoquinoline
daidzin daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).	2.1	1	7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative	plant metabolite
oleanolic acid 3-acetate oleanolic acid 3-acetate: from Gardenia jasminoides; RN given for (3beta)-isomer	2.1	1
lanosterol [no description available]	2.05	1	14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid	bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
ononin [no description available]	2.1	1	4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; monosaccharide derivative	plant metabolite
acarbose [no description available]	2.08	1	amino cyclitol; glycoside
ganoderic acid a [no description available]	4.8	5	triterpenoid
ganoderiol f ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source	3.87	3	triterpenoid
Ganodermanontriol [no description available]	3.58	2	triterpenoid	metabolite
formononetin [no description available]	2.1	1	4'-methoxyisoflavones; 7-hydroxyisoflavones	phytoestrogen; plant metabolite
luteolin [no description available]	2.1	1	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
7,3'-dihydroxy-4'-methoxyisoflavone 7,3'-dihydroxy-4'-methoxyisoflavone: isolated from Astragali radix; structure in first source. calycosin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at the 3' position and a methoxy group at the 4' position.	2.1	1	4'-methoxyisoflavones; 7-hydroxyisoflavones	antioxidant; metabolite
luteolin-7-glucoside luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.1	1	beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antioxidant; plant metabolite
apigetrin apigetrin: structure given in first source. apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.1	1	beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative	antibacterial agent; metabolite; non-steroidal anti-inflammatory drug
calycosin-7-o-beta-d-glucopyranoside calycosin-7-O-beta-D-glucoside: from Radix Astragali. calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.	2.1	1	4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative
spd-304 SPD-304: structure in first source	2.1	1
poricoic acid g poricoic acid G: from Poria cocos (Polyporaceae); structure in first source. poricoic acid G : A tricyclic triterpenoid isolated from Poria cocos.	3.17	1	dicarboxylic acid; secondary alcohol; tricyclic triterpenoid	fungal metabolite
beta-escin [no description available]	2.6	1
polyporenic acid c [no description available]	3.17	1
diosgenin glucoside diosgenin glucoside: RN given refers to (3beta,25R)-isomer; structure given in first source. diosgenin 3-O-beta-D-glucoside : A sterol 3-beta-D-glucoside having diosgenin as the sterol component.	2.1	1	hexacyclic triterpenoid; monosaccharide derivative; spiroketal; sterol 3-beta-D-glucoside	metabolite
trametenolic acid b trametenolic acid B: from Trametes lactinea; structure in first source	3.17	1	triterpenoid
ganodermadiol ganodermadiol: isolated from Ganoderma lucidum; structure given in first source. ganoderol B : A tetracyclic triterpenoid that is lanosta-7,9(11),24-triene which is substituted by hydroxy groups at positions 3 and 27. It has been isolated from several Ganoderma species.	3.58	2	3beta-sterol; primary allylic alcohol; tetracyclic triterpenoid	antiviral agent; fungal metabolite; hepatoprotective agent
astragaloside IV [no description available]	2.1	1	pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; antioxidant; EC 4.2.1.1 (carbonic anhydrase) inhibitor; neuroprotective agent; plant metabolite; pro-angiogenic agent
lucidenic acid a lucidenic acid A: isolated from fruiting bodies of Ganoderma lucidum; structure in first source	3.17	1	triterpenoid
ganoderic acid t ganoderic acid T: down-regulates expression of both MMP-2 and MMP-9; isolated from Ganoderma lucidum; structure in first source	3.17	1
ganoderic acid f ganoderic acid F: isolated from Ganoderma lucidum; structure in first source	3.59	2	triterpenoid
inotodiol inotodiol: structure in first source	3.17	1
3,7-dioxolanosta-8,24-dien-26-oic acid [no description available]	4.13	2
ganoderic acid y ganoderic acid Y: has antiviral activity; isolated from Ganoderma lucidum; structure in first source	4.13	2	triterpenoid
7-oxo-ganoderic acid z 7-oxo-ganoderic acid Z: from the mushroom Ganoderma lucidum; structure in first source	3.17	1
ganoderic acid a ganoderic acid A: isolated from Ganoderma lucidum; structure in first source	2.05	1

Condition	Relationship Strength	Studies
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.07	1
Astrocytosis [description not available]	2.07	1
Akinetic-Rigid Variant of Huntington Disease [description not available]	2.07	1
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.07	1
Huntington Disease A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)	2.07	1

chemdatabank.com